A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or Lymphoma

Lymphoma Clinical Trial

— JZAR  

Official title:

The Effect of Tasisulam on the CYP2C9-Mediated Metabolism of Tolbutamide: A Pharmacokinetic Interaction Study in Cancer Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01185548
• Other study ID #: 13076
• Secondary ID: H8K-MC-JZAR
• Status: Terminated
• Phase: Phase 1
• Start date: July 2010
• Est. completion date: December 2010

Study information

• Verified date: March 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to assess the effect of tasisulam as an inhibitor of CYP2C9, using tolbutamide as a probe substrate. This study was to have 3 treatment periods, and continued access in an extension period. Period 1 is 4 days in length. Periods 2 and 3 are each approximately 28 days in length. Due to the early termination of the trial, only 1 Period 3 participant enrolled in the extension period before study termination.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: December 2010
• Est. primary completion date: December 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Have histologically or cytologically confirmed solid malignancy or lymphoma that is advanced and/or metastatic disease which has not responded to standard therapy or for which no standard therapy exists.

2. Have given written informed consent prior to any study-specific procedures.

3. Have a performance status of less than or equal to 1 on the Eastern Cooperative Oncology Group (ECOG) scale and an estimated life expectancy of greater than 12 weeks.

4. Have discontinued all previous therapies for cancer, including chemotherapy, radiotherapy, cancer-related hormonal therapy, or other investigational therapy for at least 30 days (45 days for mitomycin-C or nitrosoureas) prior to study enrollment and recovered from the acute effects of therapy. Limited field radiotherapy is permitted (in consultation with the investigator).

5. Have adequate organ function.

6. Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

7. Males and females with reproductive potential must agree to use medically approved contraceptive precautions during the trial and for 6 months following the last dose of study drug.

8. Females with child-bearing potential must have had a negative serum pregnancy test less than 7 days prior to the first dose of study drug.

Exclusion Criteria:

1. Have received treatment within 30 days of the initial dose of study drug with an experimental agent for noncancer indications that has not received regulatory approval for any indication.

2. Have known allergies to tasisulam or related compounds.

3. Have serious preexisting medical conditions.

4. Show evidence of significant active neuropsychiatric disease or central nervous system (CNS) disease (for example, Alzheimer's disease or Parkinson's disease). Patients with active brain metastasis are excluded.

5. Have current acute or chronic leukemia.

6. Females who are pregnant or lactating.

7. Have known positive test results in human immunodeficiency virus (HIV), hepatitis B surface antigen (HBSAg), or hepatitis C antibodies (HCAb).

8. History of severe allergies or multiple adverse drug reactions.

9. Are persons who have previously completed or withdrawn from this study or any other study investigating tasisulam.

10. Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.

11. Serious concomitant systemic disorder, including diabetes or active infection, incompatible with the study.

12. Clinically significant cardiac symptomology.

13. Patients being treated with warfarin.

14. Patients being treated with sulfonylureas

15. Regularly use drugs of abuse and/or show positive findings on urinary drug screening that is not in accordance with known/acceptable concomitant medication.

16. Patients who have received medications that are known inducers or inhibitors of CYP2C9 within 30 days prior to enrollment.

17. Have donated or lost blood of more than 500 milliliter (mL) within the last month.

18. Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females) (1 unit = 12 ounces (oz) or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).

19. Failure for any reason to satisfy the investigator for adequate fitness to participate in the study.

20. Screening albumin levels less than 30 grams/Liter (g/L).

Related Conditions & MeSH terms

• Advanced Cancer
• Lymphoma
• Neoplasms

Intervention

Drug:
• Tolbutamide
Administered orally
• Tasisulam
Administered intravenously

Locations

Country	Name	City	State
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Cardiff	South Glamorgan
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Leeds	West Yorkshire
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Leicester
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	London
United Kingdom	For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.	Sheffield	Trent

Sponsors (1)

Lead Sponsor	Collaborator
Eli Lilly and Company

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics of Tolbutamide, Concurrent Dosing, Area Under the Curve (AUC 0-8)	AUC0-8 is defined as the area under the concentration time curve from time 0 to infinity.	Period 2 Predose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 6, 8, 24, 48, 72, 120, 168, 336 hours post tolbutamide dose
Secondary	Pharmacokinetics of Tolbutamide, Staggered Dosing in Period 3, Area Under the Curve (AUC 0-8)	AUC0-8 is defined as the area under the concentration time curve from time 0 to infinity.	Period 3 Predose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 24, 48, 96, and 264 hours post tolbutamide dose
Secondary	Pharmacokinetics of Tolbutamide, Maximum Concentration (Cmax)		Period 1, 2, and 3 Predose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 6, 8, 24, 48, 72, 96, 120, 168, 264, 336 hours post tolbutamide dose
Secondary	Pharmacokinetics of Tolbutamide, Observed Time at Maximal Concentration (Tmax)		Period 1, 2, and 3 Predose; and 0.5, 1, 1.5, 2, 2.5, 3, 4, 4.5, 6, 8, 24, 48, 72, 96, 120, 168, 264, 336 hours post tolbutamide dose